These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38874462)

  • 1. FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    Zschernack V; Thomas C; Schaub C; Kristiansen G; Waha A; Goschzik T; Herrlinger U; Pietsch T
    J Neuropathol Exp Neurol; 2024 Oct; 83(10):887-889. PubMed ID: 38874462
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas.
    Richardson TE; Sathe AA; Kanchwala M; Jia G; Habib AA; Xiao G; Snuderl M; Xing C; Hatanpaa KJ
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):542-548. PubMed ID: 29741737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2020 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
    Ghisai SA; van Hijfte L; Vallentgoed WR; Tesileanu CMS; de Heer I; Kros JM; Sanson M; Gorlia T; Wick W; Vogelbaum MA; Brandes AA; Franceschi E; Clement PM; Nowak AK; Golfinopoulos V; van den Bent MJ; French PJ; Hoogstrate Y
    Acta Neuropathol; 2024 Oct; 148(1):50. PubMed ID: 39382765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
    van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
    AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Astrocytoma with 1p19q codeletion].
    Ryzhova MV; Galstyan SA; Shishkina LV; Panina TN; Voronina EI; Telysheva EN; Kotelnikova AO; Starovoitov DV; Shaikhaev EG; Snigireva GP; Sycheva RV; Kadyrov SU; Adaev AR; Pitskhelauri DI; Kudieva ES; Zheludkova OG; Golanov AV
    Arkh Patol; 2023; 85(1):51-56. PubMed ID: 36785962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.
    Richardson TE; Walker JM; Hambardzumyan D; Brem S; Hatanpaa KJ; Viapiano MS; Pai B; Umphlett M; Becher OJ; Snuderl M; McBrayer SK; Abdullah KG; Tsankova NM
    Acta Neuropathol; 2024 Jul; 148(1):5. PubMed ID: 39012509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.
    Sahm F; Korshunov A; Schrimpf D; Stichel D; Jones DT; Capper D; Koelsche C; Reuss D; Kratz A; Huang K; Wefers AK; Schick M; Bewerunge-Hudler M; Mittelbronn M; Platten M; Hänggi D; Jeibmann A; Unterberg A; Herold-Mende C; Pfister SM; Brandner S; Wick W; von Deimling A
    Acta Neuropathol; 2017 Feb; 133(2):325-327. PubMed ID: 28000032
    [No Abstract]   [Full Text] [Related]  

  • 12. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
    Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
    Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
    Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
    J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
    Ammendola S; Broggi G; Barresi V
    Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
    Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
    [No Abstract]   [Full Text] [Related]  

  • 19. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
    Brat DJ; Aldape K; Colman H; Figrarella-Branger D; Fuller GN; Giannini C; Holland EC; Jenkins RB; Kleinschmidt-DeMasters B; Komori T; Kros JM; Louis DN; McLean C; Perry A; Reifenberger G; Sarkar C; Stupp R; van den Bent MJ; von Deimling A; Weller M
    Acta Neuropathol; 2020 Mar; 139(3):603-608. PubMed ID: 31996992
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.
    Noble Anbunesan S; Alfonso-Garcia A; Zhou X; Bec J; Lee HS; Jin LW; Bloch O; Marcu L
    J Biophotonics; 2023 Apr; 16(4):e202200291. PubMed ID: 36510639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.